Similar articles

• Current status of clopidogrel pharmacogenomics.

  Giusti B, Gori AM, Marcucci R, Abbate R. Giusti B, et al. Pharmacogenomics. 2012 Nov;13(15):1671-4. doi: 10.2217/pgs.12.153. Pharmacogenomics. 2012. PMID: 23171330 No abstract available.
• Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention.

  Paré G, Eikelboom JW, Sibbing D, Bernlochner I, Kastrati A. Paré G, et al. Circ Cardiovasc Interv. 2011 Oct 1;4(5):514-21; discussion 521. doi: 10.1161/CIRCINTERVENTIONS.111.962142. Circ Cardiovasc Interv. 2011. PMID: 22010190 No abstract available.
• The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

  Price MJ, Tantry US, Gurbel PA. Price MJ, et al. Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Rev Cardiovasc Med. 2011. PMID: 21546883 Review.
• The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.

  Namazi S, Kojuri J, Khalili A, Azarpira N. Namazi S, et al. Biochem Pharmacol. 2012 Apr 1;83(7):903-8. doi: 10.1016/j.bcp.2012.01.003. Epub 2012 Jan 12. Biochem Pharmacol. 2012. PMID: 22265638 Clinical Trial.
• [A current problem for regulators. Clopidogrel and pharmacokinetics].

  Zündorf I, Dingermann T. Zündorf I, et al. Pharm Unserer Zeit. 2009;38(4):360-7. doi: 10.1002/pauz.200900326. Pharm Unserer Zeit. 2009. PMID: 19572363 Review. German. No abstract available.